What did OptionCare pay for BioScrip?

OptionCare acquired BioScrip for $952.0M in 2019 (21.2x EBITDA), equivalent to 1.30x revenue. Target revenue was approximately $709.0M. Target EBITDA was approximately $45.0M.

What does BioScrip do?

BioScrip is a pharmacy business.

What multiple did OptionCare pay for BioScrip?

21.2x EBITDA and 1.30x revenue, based on disclosed deal value of $952.0M and disclosed financials.

M&A TRANSACTION · 2019

BioScrip acquired by OptionCare

$952.0M· 21.2x EBITDA· 1.30x revenue

Target

BioScrip

Acquirer

OptionCare

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$709.0M

EBITDA

$45.0M

Deal Value

$952.0M

EV/EBITDA

21.2x

Context

This $952.0M acquisition of BioScrip by OptionCare sits in the pharmacy sub-vertical. The 21.2x EBITDA multiple paid in 2019 can be compared against the population median for pharmacy transactions of similar size on our Pharmacy valuation hub. OptionCare is acquiring as a strategic buyer; see how strategic acquirers typically price pharmacy businesses on our Pharmacy strategic buyer-pool page.

Source

Data sourced from SEC filings. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own pharmacy

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the BioScrip acquisition.

Citation: ExitValue.ai. (2019). BioScrip acquired by OptionCare. https://exitvalue.ai/deals/bioscrip-acquired-by-optioncare-hc-2019-0152